While there are many drugs already available for the treatment of T2DM, over two-thirds of people with the disease continue to have suboptimal glucose control, and incretin therapies offer benefits matched by no other T2DM treatment currently available. This evidence concerns the gene GCG and type 2 diabetes mellitus.